J. M. Vallat, C. Sommer, and L. Magy, Chronic inflammatory demyelinating polyradiculoneuropathy: diagnostic and therapeutic challenges for a treatable condition, Lancet Neurol, vol.9, issue.4, pp.203-218, 2010.
URL : https://hal.archives-ouvertes.fr/hal-00629750

R. A. Hughes, D. Allen, A. Makowska, and N. A. Gregson, Pathogenesis of chronic inflammatory demyelinating polyradiculoneuropathy, J Peripher Nerv Syst, vol.11, issue.1, pp.30-46, 2006.

M. C. Dalakas, Advances in the diagnosis, pathogenesis and treatment of CIDP, Nat Rev Neurol, vol.7, issue.9, pp.507-524, 2011.

H. Koller, B. C. Kieseier, S. Jander, and H. P. Hartung, Chronic inflammatory demyelinating polyneuropathy, N Engl J Med, vol.352, issue.13, pp.1343-56, 2005.

C. D. Allen, K. M. Ansel, C. Low, R. Lesley, H. Tamamura et al., Germinal center dark and light zone organization is mediated by CXCR4 and CXCR5, Nat Immunol, vol.5, issue.9, pp.943-52, 2004.

R. A. Hughes and M. M. Mehndiratta, Corticosteroids for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev, vol.1, p.2062, 2015.

M. M. Mehndiratta and R. A. Hughes, Plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev, vol.12, p.3906, 2012.

F. Eftimov, J. B. Winer, M. Vermeulen, R. De-haan, and . Van-schaik, Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev, p.1797, 2013.

M. Mahdi-rogers, P. A. Van-doorn, and R. A. Hughes, Immunomodulatory treatment other than corticosteroids, immunoglobulin and plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev, p.3280, 2013.

D. Cocito, S. Grimaldi, I. Paolasso, Y. Falcone, G. Antonini et al., Immunosuppressive treatment in refractory chronic inflammatory demyelinating polyradiculoneuropathy. A nationwide retrospective analysis, Eur J Neurol, vol.18, issue.12, pp.1417-1438, 2011.

S. Muller, S. Brun, R. F. De-seze, J. Loeffler, J. P. Jeltsch-david et al., Autophagy in neuroinflammatory diseases, Autoimmun Rev, vol.16, issue.8, pp.856-74, 2017.

W. Beaino and E. Trifilieff, Thiopalmitoylated peptides from the peripheral nervous system myelin p0 protein: synthesis, characterization, and neuritogenic properties, Bioconjug Chem, vol.21, issue.8, pp.1439-1486, 2010.

S. Brun, W. Beaino, L. Kremer, O. Taleb, A. G. Mensah-nyagan et al., Characterization of a new rat model for chronic inflammatory demyelinating polyneuropathies, J Neuroimmunol, vol.278, pp.1-10, 2015.

V. Brinkmann, M. D. Davis, C. E. Heise, R. Albert, S. Cottens et al., The immune modulator FTY720 targets sphingosine 1-phosphate receptors, J Biol Chem, vol.277, issue.24, pp.21453-21460, 2002.

Z. Zhang, H. J. Schluesener, A. Billich, F. Bornancin, P. Devay et al., FTY720: a most promising immunosuppressant modulating immune cell functions, J Biol Chem, vol.7, issue.8, pp.47408-47423, 2003.

K. Chiba, Y. Yanagawa, Y. Masubuchi, H. Kataoka, T. Kawaguchi et al.,

, FTY720, a novel immunosuppressant, induces sequestration of circulating mature lymphocytes by acceleration of lymphocyte homing in rats. I. FTY720 selectively decreases the number of circulating mature lymphocytes by acceleration of lymphocyte homing, J Immunol, vol.160, issue.10, pp.5037-5081, 1998.

M. H. Graler and E. J. Goetzl, The immunosuppressant FTY720 down-regulates sphingosine 1-phosphate G-protein-coupled receptors, FASEB J, vol.18, issue.3, pp.551-554, 2004.

S. Mandala, R. Hajdu, J. Bergstrom, E. Quackenbush, J. Xie et al., Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists, Science, vol.296, issue.5566, pp.346-355, 2002.

M. Mehling, T. A. Johnson, J. Antel, and L. Kappos, Bar-Or A. Clinical immunology of the sphingosine 1-phosphate receptor modulator fingolimod (FTY720) in multiple sclerosis, Neurology, vol.76, issue.8, pp.20-27, 2011.

M. Mehling, V. Brinkmann, J. Antel, A. Bar-or, N. Goebels et al., FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis, Neurology, vol.71, issue.16, pp.1261-1268, 2008.

L. Kappos, J. Antel, G. Comi, X. Montalban, P. O'connor et al., Oral fingolimod (FTY720) for relapsing multiple sclerosis, N Engl J Med, vol.355, issue.11, pp.1124-1164, 2006.

L. Kappos, E. W. Radue, P. O'connor, C. Polman, R. Hohlfeld et al., A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis, N Engl J Med, vol.362, issue.5, pp.387-401, 2010.
URL : https://hal.archives-ouvertes.fr/hal-00617764

P. A. Calabresi, E. W. Radue, D. Goodin, D. Jeffery, K. W. Rammohan et al.,

, Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial, Lancet Neurol, vol.13, issue.6, pp.545-56, 2014.

J. A. Cohen, F. Barkhof, G. Comi, H. P. Hartung, B. O. Khatri et al., Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis, N Engl J Med, vol.362, issue.5, pp.402-417, 2010.
URL : https://hal.archives-ouvertes.fr/hal-00617750

Z. Zhang, Z. Y. Zhang, U. Fauser, and H. J. Schluesener, FTY720 ameliorates experimental autoimmune neuritis by inhibition of lymphocyte and monocyte infiltration into peripheral nerves, Exp Neurol, vol.210, issue.2, pp.681-90, 2008.

Z. Y. Zhang, Z. Zhang, and H. J. Schluesener, FTY720 attenuates lesional interleukin-17(+) cell accumulation in rat experimental autoimmune neuritis, Neuropathol Appl Neurobiol, vol.35, issue.5, pp.487-95, 2009.

B. Ambrosius, K. Pitarokoili, L. Schrewe, X. Pedreiturria, J. Motte et al., Fingolimod attenuates experimental autoimmune neuritis and contributes to Schwann cell-mediated axonal protection, J Neuroinflammation, vol.14, issue.1, p.92, 2017.

H. J. Kim, C. G. Jung, D. Dukala, H. Bae, R. Kakazu et al., Fingolimod and related compounds in a spontaneous autoimmune polyneuropathy, J Neuroimmunol, vol.214, issue.1-2, pp.93-100, 2009.

R. Hughes, M. C. Dalakas, I. Merkies, N. Latov, J. M. Leger et al., Oral fingolimod for chronic inflammatory demyelinating polyradiculoneuropathy (FORCIDP Trial): a double-blind, multicentre, randomised controlled trial, Lancet Neurol, vol.17, issue.8, pp.689-98, 2018.

S. Brun, N. Schall, H. Jeltsch-david, J. Seze, and S. Muller, Assessing Autophagy in Sciatic Nerves of a Rat Model that Develops Inflammatory Autoimmune Peripheral Neuropathies, vol.6, 2017.

E. E. Ubogu, Inflammatory neuropathies: pathology, molecular markers and targets for specific therapeutic intervention, Acta Neuropathol, vol.130, issue.4, pp.445-68, 2015.

J. G. Mcleod, J. D. Pollard, P. Macaskill, M. A. Spring, P. Khurana et al., Prevalence of chronic inflammatory demyelinating polyneuropathy in New South Wales, Australia. Ann Neurol, vol.46, issue.6, pp.910-913, 1999.

R. S. Laughlin, P. J. Dyck, L. J. Melton, C. Leibson, and J. Ransom, Incidence and prevalence of CIDP and the association of diabetes mellitus, vol.73, pp.39-45, 2009.

M. C. Dalakas, Clinical trials in CIDP and chronic autoimmune demyelinating polyneuropathies, J Peripher Nerv Syst, vol.17, issue.2, pp.34-43, 2012.

D. Schafflick, B. C. Kieseier, H. Wiendl, M. Zu-horste, and G. , Novel pathomechanisms in inflammatory neuropathies, J Neuroinflammation, vol.14, issue.1, p.232, 2017.

R. J. Bright, J. Wilkinson, and B. J. Coventry, Therapeutic options for chronic inflammatory demyelinating polyradiculoneuropathy: a systematic review, BMC Neurol, vol.14, p.26, 2014.

P. Ripellino, T. Fleetwood, R. Cantello, and C. Comi, Treatment of chronic inflammatory demyelinating polyneuropathy: from molecular bases to practical considerations, Autoimmune Dis, 2014.

E. Nobile-orazio, F. Gallia, F. Terenghi, and M. Bianco, Comparing treatment options for chronic inflammatory neuropathies and choosing the right treatment plan, Expert Rev Neurother, vol.17, issue.8, pp.755-65, 2017.

S. Brun, N. Schall, S. R. Bonam, K. Bigaut, A. G. Mensah-nyagan et al., An autophagy-targeting peptide to treat chronic inflammatory demyelinating polyneuropathies, J Autoimmun, vol.92, pp.114-139, 2018.

P. Huehnchen, W. Boehmerle, and M. Endres, Fingolimod therapy is not effective in a mouse model of spontaneous autoimmune peripheral polyneuropathy. Sci Rep, vol.8, p.5648, 2018.

V. Brinkmann, A. Billich, T. Baumruker, P. Heining, R. Schmouder et al.,

. Fingolimod, FTY720): discovery and development of an oral drug to treat multiple sclerosis, Nat Rev Drug Discov, vol.9, issue.11, pp.883-97, 2010.

H. Asakura, Y. Churin, B. Bauer, J. P. Boettcher, S. Bartfeld et al., Helicobacter pylori HP0518 affects flagellin glycosylation to alter bacterial motility, Mol Microbiol, vol.78, issue.5, pp.1130-1174, 2010.

X. Wang, C. Ma, J. Wu, and J. Zhu, Roles of T helper 17 cells and interleukin-17 in neuroautoimmune diseases with emphasis on multiple sclerosis and Guillain-Barre syndrome as well as their animal models, J Neurosci Res, vol.91, issue.7, pp.871-81, 2013.

L. J. Chi, W. H. Xu, Z. W. Zhang, H. T. Huang, L. M. Zhang et al., Distribution of Th17 cells and Th1 cells in peripheral blood and cerebrospinal fluid in chronic inflammatory demyelinating polyradiculoneuropathy, J Peripher Nerv Syst, vol.15, issue.4, pp.345-56, 2010.

L. Magy, Fingolimod and CIDP: insights from negative results, Lancet Neurol, 2018.

A. T. Campagnoni and W. B. Macklin, Cellular and molecular aspects of myelin protein gene expression, Mol Neurobiol, vol.2, issue.1, pp.41-89, 1988.

N. Baumann and D. Pham-dinh, Biology of oligodendrocyte and myelin in the mammalian central nervous system, Physiol Rev. avr, vol.81, issue.2, pp.871-927, 2001.

G. Rosati, The prevalence of multiple sclerosis in the world: an update, Neurol Sci. avr, vol.22, issue.2, pp.117-156, 2001.

R. Gold, C. Linington, and H. Lassmann, Understanding pathogenesis and therapy of multiple sclerosis via animal models: 70 years of merits and culprits in experimental autoimmune encephalomyelitis research, Brain. août, vol.129, pp.1953-71, 2006.

J. Nakahara, S. Aiso, and N. Suzuki, Autoimmune versus oligodendrogliopathy: the pathogenesis of multiple sclerosis, Arch Immunol Ther Exp (Warsz), vol.58, issue.5, pp.325-358, 2010.

V. K. Tuohy, Peptide determinants of myelin proteolipid protein (PLP) in autoimmune demyelinating disease: a review, Neurochem Res. août, vol.19, issue.8, pp.935-979, 1994.

R. H. Swanborg, Experimental autoimmune encephalomyelitis in rodents as a model for human demyelinating disease, Clin Immunol Immunopathol. oct, vol.77, issue.1, pp.4-13, 1995.

C. Ewing and C. C. Bernard, Insights into the aetiology and pathogenesis of multiple sclerosis, Immunol Cell Biol. févr, vol.76, issue.1, pp.47-54, 1998.

A. G. Baxter, The origin and application of experimental autoimmune encephalomyelitis, Nat Rev Immunol, vol.7, issue.11, pp.904-916, 2007.

R. Hughes and D. R. Cornblath, Guillain-Barré syndrome, Lancet, vol.5, issue.9497, pp.1653-66, 2005.

V. Cosi and M. Versino, Guillain-Barré syndrome, Neurol Sci. mars, vol.27, issue.1, pp.47-51, 2006.

S. Vucic, M. C. Kiernan, and D. R. Cornblath, Guillain-Barré syndrome: an update, J Clin Neurosci. juin, vol.16, issue.6, pp.733-774, 2009.

H. P. Hartung, B. C. Kieseier, and R. Kiefer, Progress in Guillain-Barré syndrome, Curr Opin Neurol, vol.14, issue.5, pp.597-604, 2001.

B. C. Kieseier, R. Kiefer, R. Gold, B. Hemmer, H. J. Willison et al., Advances in understanding and treatment of immune-mediated disorders of the peripheral nervous system, Muscle Nerve. août, vol.30, issue.2, pp.131-56, 2004.

C. W. Ang, B. C. Jacobs, and J. D. Laman, The Guillain-Barré syndrome: a true case of molecular mimicry, Trends Immunol. févr, vol.25, issue.2, pp.61-67, 2004.

H. J. Willison and G. M. O'hanlon, The immunopathogenesis of Miller Fisher syndrome, J Neuroimmunol. déc, vol.100, issue.1-2, pp.3-12, 1999.

J. Vallat, C. Sommer, and L. Magy, Chronic inflammatory demyelinating polyradiculoneuropathy: diagnostic and therapeutic challenges for a treatable condition, Lancet Neurol. avr, vol.9, issue.4, pp.402-414, 2010.
URL : https://hal.archives-ouvertes.fr/hal-00629750

P. J. Dyck, A. C. Lais, M. Ohta, J. A. Bastron, H. Okazaki et al., Chronic inflammatory polyradiculoneuropathy, Mayo Clin Proc. nov, vol.50, issue.11, pp.621-658, 1975.

R. Hughes, D. Allen, A. Makowska, and N. A. Gregson, Pathogenesis of chronic inflammatory demyelinating polyradiculoneuropathy, J Peripher Nerv Syst. mars, vol.11, issue.1, pp.30-46, 2006.

, Research criteria for diagnosis of chronic inflammatory demyelinating polyneuropathy (CIDP), Neurology. mai, vol.41, issue.5, pp.617-625, 1991.

F. Group, Recommendations on diagnostic strategies for chronic inflammatory demyelinating polyradiculoneuropathy, J Neurol Neurosurg Psychiatry. févr, vol.79, issue.2, pp.115-123, 2008.

G. Nicolas, T. Maisonobe, L. Forestier, N. Léger, J. Bouche et al., Proposed revised electrophysiological criteria for chronic inflammatory demyelinating polyradiculoneuropathy, Muscle Nerve. janv, vol.25, issue.1, pp.26-30, 2002.

, European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society--First Revision, Joint Task Force of the EFNS and the PNS, vol.15, pp.1-9, 2010.

T. Maisonobe, B. Chassande, M. Vérin, M. Jouni, J. M. Léger et al., Chronic dysimmune demyelinating polyneuropathy: a clinical and electrophysiological study of 93 patients, J Neurol Neurosurg Psychiatry. juill, vol.61, issue.1, pp.36-42, 1996.

J. P. Azulay, J. Pouget, J. F. Pellissier, O. Blin, and G. Serratrice, Rev Neurol (Paris), vol.148, issue.12, pp.752-61, 1992.

K. Viala, T. Maisonobe, T. Stojkovic, R. Koutlidis, X. Ayrignac et al., A current view of the diagnosis, clinical variants, response to treatment and prognosis of chronic inflammatory demyelinating polyradiculoneuropathy, J Peripher Nerv Syst. mars, vol.15, issue.1, pp.50-56, 2010.

G. Serratrice, J. P. Azulay, J. Pouget, and J. Boucraut, Variable and recurrent ptosis and ophthalmoplegia in chronic polyradiculoneuritis, Rev Neurol (Paris). avr, vol.153, issue.3, pp.197-200, 1997.

S. Attarian, J. P. Azulay, J. Boucraut, N. Escande, and J. Pouget, Terminal latency index and modified F ratio in distinction of chronic demyelinating neuropathies, Clin Neurophysiol. mars, vol.112, issue.3, pp.457-63, 2001.

S. Attarian, J. Azulay, D. Lardillier, A. Verschueren, and J. Pouget, Transcranial magnetic stimulation in lower motor neuron diseases, Clin Neurophysiol. janv, vol.116, issue.1, pp.35-42, 2005.

R. A. Lewis, A. J. Sumner, M. J. Brown, and A. K. Asbury, Multifocal demyelinating neuropathy with persistent conduction block, Neurology. sept, vol.32, issue.9, pp.958-64, 1982.

H. J. Willison and Y. N. , Peripheral neuropathies and anti-glycolipid antibodies, Brain. déc, vol.125, pp.2591-625, 2002.

S. Attarian, J. Boucraut, A. M. Hubert, D. Uzenot, E. Delmont et al., Chronic ataxic neuropathies associated with anti-GD1b IgM antibodies: response to IVIg therapy, J Neurol Neurosurg Psychiatry. janv, vol.81, issue.1, pp.61-65, 2010.
URL : https://hal.archives-ouvertes.fr/hal-00552791

S. Attarian, J. Azulay, A. Verschueren, and J. Pouget, Magnetic stimulation using a triplestimulation technique in patients with multifocal neuropathy without conduction block, Muscle Nerve. déc, vol.32, issue.6, pp.710-714, 2005.

F. Eftimov, J. B. Winer, M. Vermeulen, R. De-haan, and . Van-schaik, Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev, p.1797, 2013.

P. J. Dyck, P. C. O'brien, K. F. Oviatt, R. P. Dinapoli, J. R. Daube et al., Prednisone improves chronic inflammatory demyelinating polyradiculoneuropathy more than no treatment, Ann Neurol. févr, vol.11, issue.2, pp.136-177, 1982.

M. M. Mehndiratta, R. Hughes, and J. Pritchard, Plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy, Cochrane Database Syst Rev. 25 août, issue.8, p.3906, 2015.

J. Zhu, G. M. Deng, M. Levi, B. Wahren, A. Diab et al., Prevention of experimental autoimmune neuritis by nasal administration of P2 protein peptide 57-81, J Neuropathol Exp Neurol. mars, vol.57, issue.3, pp.291-301, 1998.

J. Zhu, S. H. Pelidou, G. Deretzi, M. Levi, E. Mix et al., P0 glycoprotein peptides 56-71 and 180-199 dose-dependently induce acute and chronic experimental autoimmune neuritis in Lewis rats associated with epitope spreading, J Neuroimmunol. 1 mars, vol.114, issue.1-2, pp.99-106, 2001.

C. M. Gabriel, R. A. Hughes, S. E. Moore, K. J. Smith, and F. S. Walsh, Induction of experimental autoimmune neuritis with peripheral myelin protein-22, Brain. oct, vol.121, pp.1895-902, 1998.

M. Mäurer and R. Gold, Animal models of immune-mediated neuropathies, Curr Opin Neurol, vol.15, issue.5, pp.617-639, 2002.

L. P. Zou, H. G. Ljunggren, M. Levi, I. Nennesmo, B. Wahren et al., P0 protein peptide 180-199 together with pertussis toxin induces experimental autoimmune neuritis in resistant C57BL/6 mice, J Neurosci Res. 1 déc, vol.62, issue.5, pp.717-738, 2000.

D. M. Calida, S. G. Kremlev, T. Fujioka, B. Hilliard, E. Ventura et al., Experimental allergic neuritis in the SJL/J mouse: induction of severe and reproducible disease with bovine peripheral nerve myelin and pertussis toxin with or without interleukin-12, J Neuroimmunol. 10 juill, vol.107, issue.1, pp.1-7, 2000.

N. Yuki, M. Yamada, M. Koga, M. Odaka, K. Susuki et al., Animal model of axonal Guillain-Barré syndrome induced by sensitization with GM1 ganglioside, Ann Neurol. juin, vol.49, issue.6, pp.712-732, 2001.

K. Susuki, Y. Nishimoto, M. Koga, T. Nagashima, I. Mori et al., Various immunization protocols for an acute motor axonal neuropathy rabbit model compared, Neurosci Lett. 16 sept, vol.368, issue.1, pp.63-70, 2004.

H. Lassmann, W. Fierz, C. Neuchrist, and R. Meyermann, Chronic relapsing experimental allergic neuritis induced by repeated transfer of P2-protein reactive T cell lines, Brain. févr, vol.114, pp.429-471, 1991.

S. Jung, S. Gaupp, T. Korn, G. Köllner, H. Hartung et al., Biphasic form of experimental autoimmune neuritis in dark Agouti rats and its oral therapy by antigenspecific tolerization, J Neurosci Res. 15 févr, vol.75, issue.4, pp.524-559, 2004.

B. Salomon, L. Rhee, H. Bour-jordan, H. Hsin, A. Montag et al., Development of spontaneous autoimmune peripheral polyneuropathy in B7-2-deficient NOD mice, J Exp Med. 3 sept, vol.194, issue.5, pp.677-84, 2001.

T. Weimbs and W. Stoffel, Proteolipid protein (PLP) of CNS myelin: positions of free, disulfide-bonded, and fatty acid thioester-linked cysteine residues and implications for the membrane topology of PLP, Biochemistry. 15 déc, vol.31, issue.49, pp.12289-96, 1992.

J. M. Greer, B. Denis, R. A. Sobel, and E. Trifilieff, Thiopalmitoylation of myelin proteolipid protein epitopes enhances immunogenicity and encephalitogenicity, J Immunol. 1 juin, vol.166, issue.11, pp.6907-6920, 2001.

N. A. Pfender, S. Grosch, G. Roussel, M. Koch, E. Trifilieff et al., Route of uptake of palmitoylated encephalitogenic peptides of myelin proteolipid protein by antigenpresenting cells: importance of the type of bond between lipid chain and peptide and relevance to autoimmunity, J Immunol. 1 févr, vol.180, issue.3, pp.1398-404, 2008.
URL : https://hal.archives-ouvertes.fr/inserm-00351007

W. Beaino and E. Trifilieff, Thiopalmitoylated peptides from the peripheral nervous system myelin p0 protein: synthesis, characterization, and neuritogenic properties, Bioconjug Chem. 18 août, vol.21, issue.8, pp.1439-1486, 2010.

M. E. Shy, Charcot-Marie-Tooth disease: an update, Curr Opin Neurol, vol.17, issue.5, pp.579-85, 2004.

A. Horga and X. Montalban, FTY720 (fingolimod) for relapsing multiple sclerosis, Expert Rev Neurother. mai, vol.8, issue.5, pp.699-714, 2008.

J. Chun and H. Hartung, Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis, Clin Neuropharmacol. avr, vol.33, issue.2, pp.91-101, 2010.

. Vidal.-monographie-du-gilenya, , 2018.

D. Luchtman, R. Gollan, E. Ellwardt, J. Birkenstock, K. Robohm et al., In vivo and in vitro effects of multiple sclerosis immunomodulatory therapeutics on glutamatergic excitotoxicity, J Neurochem. mars, vol.136, issue.5, pp.971-80, 2016.

S. Rossi, T. Lo-giudice, D. Chiara, V. Musella, A. Studer et al., Oral fingolimod rescues the functional deficits of synapses in experimental autoimmune encephalomyelitis, Br J Pharmacol. févr, vol.165, issue.4, pp.861-870, 2012.

, ClinicalTrials.gov. FORCIDP, ClinicalTrials.gov Identifier NCT01625182

P. Van-den-bergh and Y. A. Rajabally, Chronic inflammatory demyelinating polyradiculoneuropathy, Presse Med. juin, vol.42, issue.6, pp.203-215, 2013.

P. Van-den-bergh and F. Piéret, Electrodiagnostic criteria for acute and chronic inflammatory demyelinating polyradiculoneuropathy, Muscle Nerve. avr, vol.29, issue.4, pp.565-74, 2004.

H. Köller, B. C. Kieseier, S. Jander, and H. Hartung, Chronic inflammatory demyelinating polyneuropathy, N Engl J Med. 31 mars, vol.352, issue.13, pp.1343-56, 2005.

T. Harbo, H. Andersen, and J. Jakobsen, Length-dependent weakness and electrophysiological signs of secondary axonal loss in chronic inflammatory demyelinating polyradiculoneuropathy, Muscle Nerve. août, vol.38, issue.2, pp.1036-1081, 2008.

C. Vital, A. Vital, A. Lagueny, X. Ferrer, D. Fontan et al., Chronic inflammatory demyelinating polyneuropathy: immunopathological and ultrastructural study of peripheral nerve biopsy in 42 cases, Ultrastruct Pathol. déc, vol.24, issue.6, pp.363-372, 2000.

C. Sommer, S. Koch, M. Lammens, A. Gabreels-festen, G. Stoll et al., Macrophage clustering as a diagnostic marker in sural nerve biopsies of patients with CIDP, Neurology. 27 déc, vol.65, issue.12, pp.1924-1933, 2005.

L. J. Chi, W. H. Xu, Z. W. Zhang, H. T. Huang, L. M. Zhang et al., Distribution of Th17 cells and Th1 cells in peripheral blood and cerebrospinal fluid in chronic inflammatory demyelinating polyradiculoneuropathy, J Peripher Nerv Syst. déc, vol.15, issue.4, pp.345-56, 2010.

Z. Zhang, Z. Zhang, and H. J. Schluesener, FTY720 attenuates lesional interleukin-17(+) cell accumulation in rat experimental autoimmune neuritis, Neuropathol Appl Neurobiol, vol.35, issue.5, pp.487-95, 2009.

I. Horiuchi, H. Ochi, H. Murai, M. Osoegawa, M. Minohara et al., Th2 shift in mononeuritis multiplex and increase of Th2 cells in chronic inflammatory demyelinating polyneuropathy: an intracellular cytokine analysis, J Neurol Sci. 15 déc, vol.193, issue.1, pp.49-52, 2001.

F. Madia, G. Frisullo, V. Nociti, A. Conte, M. Luigetti et al., pSTAT1, pSTAT3, and T-bet as markers of disease activity in chronic inflammatory demyelinating polyradiculoneuropathy, J Peripher Nerv Syst. juin, vol.14, issue.2, pp.107-124, 2009.

M. Rentzos, A. V. Angeli, A. Rombos, A. Kyrozis, C. Nikolaou et al., Proinflammatory cytokines in serum and cerebrospinal fluid of CIDP patients, Neurol Res, vol.34, issue.9, pp.842-848, 2012.

W. X. Yan, J. Taylor, S. Andrias-kauba, and J. D. Pollard, Passive transfer of demyelination by serum or IgG from chronic inflammatory demyelinating polyneuropathy patients, Ann Neurol. juin, vol.47, issue.6, pp.765-75, 2000.

M. C. Dalakas and M. , Advances in the diagnosis, pathogenesis and treatment of CIDP, Nat Rev Neurol. 16 août, vol.7, issue.9, pp.507-524, 2011.

E. E. Ubogu, Inflammatory neuropathies: pathology, molecular markers and targets for specific therapeutic intervention, Acta Neuropathol, vol.130, issue.4, pp.445-68, 2015.

M. C. Dalakas, Clinical trials in CIDP and chronic autoimmune demyelinating polyneuropathies, J Peripher Nerv Syst. mai, vol.17, issue.2, pp.34-43, 2012.

D. Schafflick, B. C. Kieseier, H. Wiendl, M. Zu-horste, and G. , Novel pathomechanisms in inflammatory neuropathies, J Neuroinflammation, vol.14, issue.1, p.232, 2017.

R. J. Bright, J. Wilkinson, and B. J. Coventry, Therapeutic options for chronic inflammatory demyelinating polyradiculoneuropathy: a systematic review, BMC Neurol. 7 févr, vol.14, p.26, 2014.

P. Ripellino, T. Fleetwood, R. Cantello, and C. Comi, Treatment of chronic inflammatory demyelinating polyneuropathy: from molecular bases to practical considerations, Autoimmune Dis, 2014.

S. Brun, N. Schall, S. R. Bonam, K. Bigaut, A. Mensah-nyagan et al., An autophagy-targeting peptide to treat chronic inflammatory demyelinating polyneuropathies, J Autoimmun. août, vol.92, pp.114-139, 2018.

H. Kim, C. Jung, D. Dukala, H. Bae, R. Kakazu et al., Fingolimod and related compounds in a spontaneous autoimmune polyneuropathy, J Neuroimmunol. 29 sept, vol.214, issue.1-2, pp.93-100, 2009.

P. Huehnchen, W. Boehmerle, and M. Endres, Fingolimod therapy is not effective in a mouse model of spontaneous autoimmune peripheral polyneuropathy, vol.8, p.5648, 2018.

Z. Zhang, Z. Zhang, U. Fauser, and H. J. Schluesener, FTY720 ameliorates experimental autoimmune neuritis by inhibition of lymphocyte and monocyte infiltration into peripheral nerves, Exp Neurol. avr, vol.210, issue.2, pp.681-90, 2008.

S. Mandala, R. Hajdu, J. Bergstrom, E. Quackenbush, J. Xie et al., Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists, Science. 12 avr, vol.296, issue.5566, pp.346-355, 2002.

V. Brinkmann, A. Billich, T. Baumruker, P. Heining, R. Schmouder et al., Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis, Nat Rev Drug Discov, vol.9, issue.11, pp.883-97, 2010.

H. Asakura, Y. Churin, B. Bauer, J. P. Boettcher, S. Bartfeld et al., Helicobacter pylori HP0518 affects flagellin glycosylation to alter bacterial motility, Mol Microbiol. déc, vol.78, issue.5, pp.1130-1174, 2010.

X. Wang, C. Ma, J. Wu, and J. Zhu, Roles of T helper 17 cells and interleukin-17 in neuroautoimmune diseases with emphasis on multiple sclerosis and Guillain-Barré syndrome as well as their animal models, J Neurosci Res. juill, vol.91, issue.7, pp.871-81, 2013.

R. Hughes, M. C. Dalakas, I. Merkies, N. Latov, J. Léger et al., Oral fingolimod for chronic inflammatory demyelinating polyradiculoneuropathy (FORCIDP Trial): a double-blind, multicentre, randomised controlled trial, Lancet Neurol. août, vol.17, issue.8, pp.689-98, 2018.

L. Magy, Fingolimod and CIDP: insights from negative results, Liste des communications orales et par affiche, vol.17, pp.655-661, 2018.

, Annexe 2 : Poster JNLF 2014 : Validation et caractérisation d'un modèle animal de polyradiculonévrite chronique

L. Kremer, S. Brun, W. Beaino, O. Taleb, D. Lam et al., Characterization of a new animal mode of chronic inflammatory demyelinating polyneuropathy, vol.3, 2014.

L. Kremer, S. Brun, W. Beaino, O. Taleb, D. Lam et al., Poster JNLF 2015 : Effet du FTY720 (Fingolimod) chez un nouveau modèle animal préclinique de polyradiculonévrite inflammatoire démyélinisante chronique, vol.4

L. S-brun, E. Kremer, J. Trifilieff, and A. De-seze,

J. Poster, Validation et caractérisation d'un modèle animal de polyradiculonévrite chronique, 2014.

L. Kremer, S. Brun, W. Beaino, O. Taleb, D. Lam et al.,

A. Poster, Characterization of a new animal mode of chronic inflammatory demyelinating polyneuropathy, 2014.

L. Kremer, S. Brun, W. Beaino, O. Taleb, D. Lam et al.,

J. Poster, , 2015.

, Effet du FTY720 (Fingolimod) chez un nouveau modèle animal préclinique de polyradiculonévrite inflammatoire démyélinisante chronique

L. Kremer, E. Brun, and . Trifilieff, J. de Seze ANNEXE, vol.5

A. Poster, Effect of FTY720 (Fingolimod) in a new preclinical rat model for chronic inflammatory demyelinating polyneuropathy (CIDP), 2015.

L. S-brun, E. Kremer, J. Trifilieff, and . De-seze,